204 related articles for article (PubMed ID: 31911540)
21. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
Lu H; Villafane N; Dogruluk T; Grzeskowiak CL; Kong K; Tsang YH; Zagorodna O; Pantazi A; Yang L; Neill NJ; Kim YW; Creighton CJ; Verhaak RG; Mills GB; Park PJ; Kucherlapati R; Scott KL
Cancer Res; 2017 Jul; 77(13):3502-3512. PubMed ID: 28512244
[TBL] [Abstract][Full Text] [Related]
22. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
23. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
24. Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.
Meador CB; Pao W
Cancer Discov; 2015 Apr; 5(4):348-50. PubMed ID: 25847954
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
26.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
27. The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids.
Duong HQ; Nemazanyy I; Rambow F; Tang SC; Delaunay S; Tharun L; Florin A; Büttner R; Vandaele D; Close P; Marine JC; Shostak K; Chariot A
Cancer Res; 2018 Aug; 78(16):4533-4548. PubMed ID: 29915160
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
29. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
30. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
31. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Case Series Analysis of
Hendifar A; Blais EM; Wolpin B; Subbiah V; Collisson E; Singh I; Cannon T; Shaw K; Petricoin EF; Klempner S; Lyons E; Wang-Gillam A; Pishvaian MJ; O'Reilly EM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476331
[TBL] [Abstract][Full Text] [Related]
33. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
[TBL] [Abstract][Full Text] [Related]
34. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
35. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Schrock AB; Zhu VW; Hsieh WS; Madison R; Creelan B; Silberberg J; Costin D; Bharne A; Bonta I; Bosemani T; Nikolinakos P; Ross JS; Miller VA; Ali SM; Klempner SJ; Ou SI
J Thorac Oncol; 2018 Sep; 13(9):1312-1323. PubMed ID: 29883838
[TBL] [Abstract][Full Text] [Related]
36. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
37. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
38. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA
PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244
[TBL] [Abstract][Full Text] [Related]
39. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
40. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
